Ramón
García Sanz
Profesor Titular de Universidad
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (20)
2023
-
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
Expert Review of Hematology, Vol. 16, Núm. 11, pp. 835-847
-
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
Future Oncology, Vol. 19, Núm. 5, pp. 345-353
-
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Seminars in Hematology
-
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Seminars in Hematology
-
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106
2022
-
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62
2020
-
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Blood, Vol. 136, Núm. 21, pp. 2401-2409
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
-
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1165-1170
-
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018
2019
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
2018
-
Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom's macroglobulinemia
New England Journal of Medicine, Vol. 378, Núm. 25, pp. 2399-2410
2017
-
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
2013
-
International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease
Journal of Clinical Oncology, Vol. 31, Núm. 18, pp. 2347-2357
2010
-
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269
-
The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group
Leukemia, Vol. 24, Núm. 10, pp. 1700-1712
2009
-
International prognostic scoring system for Waldenström macroglobulinemia
Blood, Vol. 113, Núm. 18, pp. 4163-4170
2006
-
Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia
Blood, Vol. 107, Núm. 9, pp. 3442-3446